ES2472290B1 - ANTIBODIES FOR THE DETECTION AND QUANTIFICATION OF ANTICOAGULATING AGENTS - Google Patents

ANTIBODIES FOR THE DETECTION AND QUANTIFICATION OF ANTICOAGULATING AGENTS Download PDF

Info

Publication number
ES2472290B1
ES2472290B1 ES201231836A ES201231836A ES2472290B1 ES 2472290 B1 ES2472290 B1 ES 2472290B1 ES 201231836 A ES201231836 A ES 201231836A ES 201231836 A ES201231836 A ES 201231836A ES 2472290 B1 ES2472290 B1 ES 2472290B1
Authority
ES
Spain
Prior art keywords
quantification
antibodies
detection
caoc
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES201231836A
Other languages
Spanish (es)
Other versions
ES2472290A1 (en
Inventor
Juan Pablo SALVADOR VICO
M. Pilar MARCO COLÁS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina CIBERBBN
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina CIBERBBN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina CIBERBBN filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201231836A priority Critical patent/ES2472290B1/en
Priority to PCT/ES2013/070816 priority patent/WO2014083226A1/en
Publication of ES2472290A1 publication Critical patent/ES2472290A1/en
Application granted granted Critical
Publication of ES2472290B1 publication Critical patent/ES2472290B1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos para la detección y cuantificación de agentes anticoagulantes.#La presente invención se relaciona con el diseño de haptenos estructuralmente relacionados con compuestos anticoagulantes orales de tipo coumarínico (CAOC) con el objetivo de ser usados para la producción de anticuerpos específicos contra este tipo de sustancias y la posterior utilización de éstos para el desarrollo de herramientas de diagnóstico de uso en laboratorio o en dispositivos point-of-care (PoC). En particular, con los anticuerpos producidos se ha desarrollado una herramienta de diagnóstico que permite la cuantificación de los niveles plasmáticos de CAOC en pacientes tratados con este tipo de fármacos.Antibodies for the detection and quantification of anticoagulant agents. # The present invention relates to the design of haptens structurally related to coumarin-type oral anticoagulant compounds (CAOC) in order to be used for the production of specific antibodies against such substances. and the subsequent use of these for the development of diagnostic tools for use in the laboratory or in point-of-care (PoC) devices. In particular, with the antibodies produced, a diagnostic tool has been developed that allows quantification of plasma levels of CAOC in patients treated with this type of drugs.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

--

imagen22image22

imagen23image23

--

imagen24image24

imagen25image25

imagen26image26

imagen27image27

imagen28image28

imagen29image29

imagen30image30

imagen31image31

imagen32image32

imagen33image33

imagen34image34

imagen35image35

imagen36image36

imagen37image37

imagen38image38

imagen39image39

imagen40image40

imagen41image41

imagen42image42

imagen43image43

imagen44image44

imagen45image45

imagen46image46

imagen47image47

imagen48image48

imagen49image49

imagen50image50

imagen51image51

imagen52image52

imagen53image53

imagen54image54

imagen55image55

imagen56image56

imagen57image57

Claims (1)



 imagen1image 1 imagen2image2 imagen3image3 imagen4image4 imagen5image5 imagen6image6
ES201231836A 2012-11-27 2012-11-27 ANTIBODIES FOR THE DETECTION AND QUANTIFICATION OF ANTICOAGULATING AGENTS Withdrawn - After Issue ES2472290B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201231836A ES2472290B1 (en) 2012-11-27 2012-11-27 ANTIBODIES FOR THE DETECTION AND QUANTIFICATION OF ANTICOAGULATING AGENTS
PCT/ES2013/070816 WO2014083226A1 (en) 2012-11-27 2013-11-26 Antibodies for detecting and quantifying anticoagulant agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231836A ES2472290B1 (en) 2012-11-27 2012-11-27 ANTIBODIES FOR THE DETECTION AND QUANTIFICATION OF ANTICOAGULATING AGENTS

Publications (2)

Publication Number Publication Date
ES2472290A1 ES2472290A1 (en) 2014-06-30
ES2472290B1 true ES2472290B1 (en) 2015-02-25

Family

ID=50827220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201231836A Withdrawn - After Issue ES2472290B1 (en) 2012-11-27 2012-11-27 ANTIBODIES FOR THE DETECTION AND QUANTIFICATION OF ANTICOAGULATING AGENTS

Country Status (2)

Country Link
ES (1) ES2472290B1 (en)
WO (1) WO2014083226A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824645B (en) * 2019-02-28 2020-10-27 中国农业大学 Warfarin hapten and artificial antigen as well as preparation method and application thereof
CN110563712A (en) * 2019-09-23 2019-12-13 中国农业大学 synthesis and application of Kaempferia galamensis hapten

Also Published As

Publication number Publication date
WO2014083226A1 (en) 2014-06-05
ES2472290A1 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
ES2582284T3 (en) Composition comprising anaerobically cultured human intestinal microbiota
CY1117615T1 (en) THEIAZOLIS SULFONAMIDIS AND OXAZOLIS COMPOUNDS
CL2019001714A1 (en) Amino-triazolopyridine compounds and their use in the treatment of cancer.
CL2017000902A1 (en) Ror-gamma inhibitor dihydropyrrolopyridines
PE20150646A1 (en) METHODS OF TREATING A TAUOPATHY
CL2014002093A1 (en) Piperidinopyrimidine derivative compounds; pharmaceutical composition that includes them; Use in the treatment of viral infections.
CR20150326A (en) AUTOTAXIN INHIBITORS
CU20170172A7 (en) 4,6-DIAMINOQUINOLIN-3-CARBONITRILS SUBSTITUTED USEFUL AS ANALGESIC, ANTIPIRÉTIC OR ANTIINFLAMATORIOS AND ANTINEOPLÁSICOS AGENTS
CL2013003019A1 (en) Compounds derived from benzothiazole; pharmaceutical composition that includes them; and its use in the treatment of hiv.
CL2015001756A1 (en) Compounds derived from polycyclic carbamoylpyridone; pharmaceutical composition that includes them; and its use for the treatment of a hiv infection in a human who has or is at risk of having the infection.
CR20150436A (en) NEW OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND -PIRIDINA-FENILO
CR20140275A (en) SUBSTITUTED TRIAZOLOPIRIDINS
CR20160419A (en) NEW BICYCLE COMPOUNDS
ES2421956B1 (en) NEW CRYSTAL FORM OF SITAGLIPTINA SULFATE
CL2013001338A1 (en) Compounds derived from substituted benzothiene-pyridines, hiv replication inhibitors; pharmaceutical composition that includes them; pharmaceutical combination; pharmaceutical kit; and its use for the treatment of hiv.
GT201700023A (en) OPTIONALLY CONDENSED HYDERO-CYCLIC DERIVATIVES OF PIRIDIMINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES
CL2016001266A1 (en) New octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrol-2-yl.
NI201500096A (en) CHEMICAL COMPOUNDS
DOP2012000312A (en) SUBSTITUTED TRIAZOLOPIRIDINS
CL2015002837A1 (en) Pyridinylpyrazoloquinoline compounds.
CL2017000682A1 (en) Novel imidazopyridazine compounds and their use.
UY35455A (en) TRIPEPTIDIC INHIBITORS OF PROTEASA EPOXYCETONE
UY35332A (en) PIRROLOTRIAZINE DERIVATIVES AS PI3K INHIBITORS
UY35602A (en) NEW COMPOUNDS FOR CANCER TREATMENT
CO6990738A2 (en) Anticoagulant Reversion Agents

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2472290

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150225

FA2A Application withdrawn

Effective date: 20160323